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P olypoidal choroidal vasculopathy (PCV) is a sub-type of exudative age-related macular degenera-
tion (AMD) characterized by multiple,  terminal,  red-
dish-orange polypoidal lesions and a branching vascular 
network that is visible by indocyanine green angiogra-
phy (ICGA) [1 , 2].  The prevalence of PCV is higher in 
Asian patients than Western patients and accounts for 
nearly half of the presumed AMD cases in Japan [3 , 4].  
Although the visual prognosis for PCV has been 
reported to be better than that for exudative AMD,  the 
incidence of subretinal hemorrhage in patients with 
PCV is higher than the incidence in patients with AMD,  
and PCV has been shown to cause occasional,  massive 
submacular hemorrhages that can eventually result in 
chorioretinal atrophy and permanent vision loss [5-8].
The primary cause of submacular hemorrhage in 
PCV is the rupture of polypoidal lesions [3 , 6].  
Polypoidal lesions are the cause of not only submacular 
hemorrhages but also recurrent fluid accumulation and 
lipid exudation.  Therefore,  the regression of polyps,  
along with the regression of retinal exudation,  is con-
Acta Med.  Okayama,  2018
Vol.  72,  No.  4,  pp.  379-385
CopyrightⒸ 2018 by Okayama University Medical School.
http ://escholarship.lib.okayama-u.ac.jp/amo/Original Article
Impact of Polyp Regression on 2-year Outcomes of Intravitreal  
Aflibercept Injections: A Treat-and-Extend Regimen for  
Polypoidal Choroidal Vasculopathy
Mio Morizane-Hosokawa,  Yuki Morizane＊,  Shuhei Kimura,  Yusuke Shiode,   
Masayuki Hirano,  Shinichiro Doi,  Shinji Toshima,  Mika Hosogi,   
Atsushi Fujiwara,  and Fumio Shiraga
Department of Ophthalmology,  Okayama University Graduate School of Medicine,   
Dentistry and Pharmaceutical Sciences,  Okayama 700-8558,  Japan
We conducted intravitreal aflibercept injections (IVAs) for 37 Japanese patients (28 males,  9 females,  mean age 
73.4 years) with polypoidal choroidal vasculopathy (PCV),  with a treat-and-extend regimen (TER).  We evalu-
ated the impact of polyp regression after a loading dose (2-mg IVA 1 × /month for 3 months) on the patients’ 
2-year treatment outcomes.  Thirty-seven eyes were treated with IVA by a TER for 2 years.  We divided the 
patients into 2 groups based on their polyp status after the loading dose: polyp regression (PR+) (n = 19) and no 
polyp regression (PR−) (n = 18).  We compared the groups’ best-corrected visual acuity (BCVA),  central retinal 
thickness (CRT),  recurrence rate,  total number of injections,  and final treatment interval.  Both the BCVA and 
CRT were significantly improved by the treatment in both groups,  with no between-group difference in the 
amount of change (p= 0.769).  In the polyp regression (+) group,  recurrence was significantly less common 
(p= 0.03), the mean total number of injections was significantly lower (p= 0.013),  and the mean treatment inter-
val was significantly longer (0.042).  Regarding the 2-year outcomes for PCV,  the eyes with post-loading-dose 
polyp regression demonstrated less frequent recurrence and required fewer numbers of injections compared to 
the eyes without polyp regression.
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sidered one of the main goals of initial therapy in PCV 
treatment [3].  However,  the relationships between the 
long-term visual acuity outcome and the number of 
anti-vascular endothelial growth factor (VEGF) drug 
injections with the regression of polyps are not yet 
known.  In the EVEREST study,  a prospective,  multi-
center clinical trial that compared the efficacy of differ-
ent treatment methods for PCV,  the regression of pol-
yps was not associated with the change in visual acuity 
6 months after the initiation of treatment [5].  It is 
therefore necessary to investigate the association 
between polyp regression and long-term PCV treatment 
progress,  which can be evaluated by factors such as 
changes in visual acuity,  the recurrence of retinal exu-
dation,  and the number of anti-VEGF drug injections.
Treatment for PCV can consist of photodynamic 
therapy (PDT),  intravitreal injections of anti-VEGF 
drugs,  or a combination of both.  Photodynamic ther-
apy is reported to yield a higher likelihood of polyp 
regression than anti-VEGF drugs such as ranibizumab 
[5]; however,  PDT may also induce subretinal hemor-
rhages,  retinal pigment epithelial tears,  and/or chorio-
capillaris atrophy [9-11].  The risk of serious complica-
tions (such as subretinal hemorrhages) is reported to be 
lower in anti-VEGF therapy than in PDT [5 , 12].
As one of the drugs used for anti-VEGF therapy,  
aflibercept (Eylea®; Bayer HealthCare,  Berlin,  
Germany),  a recombinant fusion protein that binds to 
members of the VEGF family,  was recently reported to 
be effective for improvement of visual acuity and 
regression of polypoidal lesions in PCV [13-15].  
Regarding the treatment regimens using intravitreal 
injections of aflibercept,  fixed regimens,  pro re nata 
regimens (PRN: the as-needed approach),  and treat-
and-extend regimens (TERs) have been used [16-18].  
Among these,  a TER is an individualized regimen that 
aims to decrease the patient’s number of clinic visits and 
number of injections by determining the optimal treat-
ment interval [19]; i.e.,  the interval between injections 
is extended gradually after the resolution of the retinal 
exudation is confirmed.  The interval between injections 
is shortened when retinal exudation recurs.
In one of the typical TER protocols,  patients are 
initially treated with an anti-VEGF drug 1 × /month for 
3 months as loading dose in order to maintain the drug 
concentration in the treated eye [20 , 21].  In our prior 
study of 37 patients,  our use of a TER of aflibercept for 
PCV provided significant improvement in visual acuity 
at 1 year [21].  However,  the long-term treatment out-
comes including the association between the TER and 
polyp regression are unknown.
In the present study,  we conducted a TER of intrav-
itreal aflibercept injections (IVAs) for 37 patients with 
PCV and followed-up the patients for 2 years.  We also 
assessed the occurrence of polyp regression after the 
loading dose to determine the effects of polyp regres-
sion on visual acuity,  the recurrence of retinal exuda-
tion,  the number of anti-VEGF drug injections,  and the 
intervals between injections.
Patients and Methods
Patient selection. We retrospectively reviewed 
the medical records of 37 eyes of 37 consecutive 
Japanese patients with treatment-naive PCV who had 
been treated with IVA by a treat-and-extend regimen for 
at least 2 years at the Okayama University Graduate 
School of Medicine,  Dentistry and Pharmaceutical 
Sciences starting between June 2013 and December 
2014.  The institutional review board of this institution 
approved this retrospective study,  which was con-
ducted according to the tenets of the 1964 Helsinki 
Declaration.  Each patient was informed of the risks and 
benefits of treatment and gave written informed con-
sent.
PCV was diagnosed based on the presence of abnor-
mal branching vascular networks and characteristic 
polypoidal vascular lesions seen on ICGA images [1 , 5].  
Eyes with other retinal diseases,  e.g.,  diabetic retinop-
athy,  retinal vein occlusion,  or myopic degeneration,  
were excluded from this study,  as were eyes that had 
undergone a vitrectomy.  During the relevant time 
period,  a total of 45 consecutive patients with treat-
ment-naïve PCV started aflibercept therapy using a 
TER.  However,  8 of these patients were excluded from 
the study: 5 patients were excluded because they 
received treatment based on a PRN for the second year 
after undergoing aflibercept therapy by a TER for 1 year,  
and the remaining 3 were excluded because they were 
considered to be non-responders after 1 year and were 
switched to a different treatment for the second year (2 
patients: combination therapy with PDT and afliber-
cept; 1 patient: intravitreal ranibizumab injection 
therapy).
Ophthalmologic examinations. All patients 
underwent a comprehensive ophthalmologic examina-
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tion at all visits,  which included the measurement of 
decimal best-corrected visual acuity (BCVA) using a 
Landolt C acuity chart at 5 meters as well as intraocular 
pressure measurement,  indirect ophthalmoscopy,  slit-
lamp biomicroscopy with a contact lens,  and optical 
coherence tomography (OCT; swept-source OCT,  DRI 
OCT-1 Atlantis,  Topcon,  Tokyo or spectral-domain 
OCT,  Spectralis; Heidelberg Engineering,  Heidelberg,  
Germany).  Fluorescein angiography (FA) and ICGA 
were performed at the baseline,  3 months,  and 12 
months after the first aflibercept injection and were 
obtained using the Heidelberg Retina Angiograph sys-
tem (Heidelberg Engineering) with a confocal scanning 
laser ophthalmoscope.  The greatest linear dimension 
(GLD) of the lesions was measured by both FA and 
ICGA.  The GLD on the fluorescein angiography includes 
areas of dye leakage,  pigment epithelial detachments,  
and subretinal hemorrhages.  The GLD on the indocy-
anine green angiography includes areas of polypoidal 
lesions and abnormal branching vascular networks.  The 
regression of polypoidal lesions was evaluated by ICGA 
at 3 and 12 months after the first injection.
Intravitreal aflibercept therapy by a treat-and-ex-
tend regimen. All patients were initially treated with 
an IVA (2 mg) once per month for 3 months as the 
loading dose.  The monthly injections continued until 
no retinal exudates (i.e.,  new subretinal hemorrhage or 
subretinal and/or intraretinal fluid) were observed on 
OCT or slit-lamp biomicroscopy.  When the retinal 
exudates were resolved,  the interval to the next injec-
tion and follow-up period was extended by 2 weeks up 
to a maximum of 16 weeks,  at which point the treat-
ment was maintained at that interval.  If the exudation 
recurred,  the interval was shortened by 2 weeks to a 
minimum interval of 4 weeks.  The interval was short-
ened in increments of 4-6 weeks if the exudation 
recurred when the interval between injections was ≥ 14 
weeks.
Outcome measures. We divided the patients into 
2 groups on the basis of their ICGA results after the 
loading dose: a polyp regression (PR+) group (n = 19) 
and a no-polyp regression (PR−) group (n = 18).  The 
main outcome measure was the change in BCVA at 2 
years from the baseline.  The secondary outcomes were 
the change in the central retinal thickness (CRT),  the 
recurrence rate of PCV,  the total number of injections 
during the 2-year follow-up,  and the interval between 
injections at 2 years.
Statistical analysis. The BCVA was converted to 
the logarithm of the minimum angle of resolution (log-
MAR) units for the statistical analysis.  Differences in 
categorical and continuous variables between the two 
patient groups were tested by Fisher’s exact test and the 
Mann-Whitney U-test,  respectively.  We used a paired 
t-test analysis to examine the differences in the logMAR 
BCVA and CRT values from the baseline to the 2-year 
point.  All statistical analyses were performed with SPSS 
ver. 22.0 software (IBM,  Armonk,  NY,  USA).  A 
p-value < 0.05 was considered significant.
Results
Baseline characteristics. A total of 37 eyes of 37 
treatment-naive patients with PCV (28 males,  9 females) 
who underwent aflibercept treatment with a TER were 
enrolled.  All patients were Japanese,  and the study 
group had a mean age of 73.4 years with a range of 
55-87 years.
As noted above,  there were 19 eyes (51.4%) in the 
PR+ group and 18 eyes (48.6%) in the PR− group.  The 
mean baseline logMAR BCVA values were 0.37 ± 0.33 
in the PR+ group and 0.42 ± 0.41 in the PR− group 
(Table 1).  There was no significant difference in base-
line BCVA values between the 2 groups (p = 0.830).  
Further,  there were no significant baseline differences 
between the groups with respect to age,  sex,  CRT,  GLD 
on FA,  GLD on ICGA,  number of polyps,  or size of the 
largest polyp (Table 1).
Visual acuity outcomes. In all 37 eyes,  the mean 
logMAR BCVA significantly improved,  from 0.39 ± 0.36 
at baseline to 0.21 ± 0.30 at year 2 (p < 0.001).  The mean 
logMAR BCVA in the PR+ group improved signifi-
cantly,  from 0.37 ± 0.33 (range −0.08 to 1.00) at baseline 
to 0.17 ± 0.27 (range −0.08 to 0.08) at year 2 (p = 0.001).  
The mean logMAR BCVA in the PR− group also 
improved significantly,  from 0.42 ± 0.41 (range 0.00 to 
1.52) at baseline to 0.25 ± 0.33 (range −0.08 to 1.22) at 
year 2 (p = 0.001).  There was no significant difference 
between the 2 groups in the mean change in BCVA 
from the baseline to year 2 (p = 0.769; Table 2).  Fig. 1 
illustrates the changes in mean BCVA from baseline 
throughout the follow-up period for each group.
Central retinal thickness. In all 37 eyes,  the mean 
CRT decreased significantly,  from 346.1 ± 111.4 μm at 
baseline to 206.5 ± 68.7 μm at year 2 (p < 0.001).  The 
mean CRT in the PR+ group decreased significantly,  
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from 339.9 ± 118.2 μm (range 153-677 μm) at baseline 
to 196.1 ± 65.7 μm (range 124-341 μm) at year 2 
(p < 0.001).  The mean CRT in the PR− group also 
decreased significantly,  from 352.7 ± 106.8 μm (range 
208-627 μm) at baseline to 217.6 ± 72.0 μm (range 153-
384) at year 2 (p < 0.001).  There was no significant dif-
ference between the groups in the mean change in CRT 
from baseline to year 2 (p= 0.595,  Table 2).  Fig. 2 shows 
the changes in mean CRT from baseline throughout the 
follow-up period in each group.
Recurrence rate. Recurrence of PCV within 2 
years was observed in 22 eyes (59.5%).  PCV recurred in 
eight eyes (42.1%) in the PR+ group and in 14 eyes 
(77.8%) in the PR− group,  and this difference was sig-
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Table 1　 Baseline clinical characteristics of PCV patients grouped by polyp regression after a loading dose of intravitreal aﬂibercept 
injections
Polyp regression (＋)
after a loading dose (n＝19)
Polyp regression (－)
after a loading dose (n＝18) p
Age,  mean±SD 74.6±6.7 72.1±8.5 0.303
Male sex,  n (%) 13 (68.2%) 15 (83.3%) 0.252
Baseline BCVA (LogMAR),  mean±SD 0.37±0.33 0.42±0.41 0.830
CRT (µm),  mean±SD 339.9±118.2 352.7±106.8 0.704
GLD on FA (µm),  mean±SD 3,500±1,432 3,616±1,784 0.832
GLD on ICGA (µm),  mean±SD 2,462±1,073 2,313±766 0.751
Number of polyps,  mean±SD 2.9±2.2 3.3±1.4 0.279
PCV,  polypoidal choroidal vasculopathy; BCVA,  best-corrected visual acuity; LogMAR,  logarithm of the minimum angle of resolution;  
CRT,  central retinal thickness; GLD,  greatest linear dimension; FA,  ﬂuorescein angiography; ICGA,  indocyanine green angiography; SD,  
standard deviation.
Table 2　 Two-year outcomes of the aﬂibercept therapy with a treat-and-extend regimen for PCV in patients grouped by polyp regression 
after the loading dose
Polyp regression (＋)
after a loading dose (n＝19)
Polyp regression (－)
after a loading dose (n＝18) p
BCVA (LogMAR) change from baseline,  mean±SD －0.20±0.26 －0.17±0.18 0.769
CRT change from baseline (µm),  mean±SD －143.8±102.0 －135.1±113.4 0.595
Recurrence during 2 years,  n (%) 8 (42.1%) 14 (77.8%) 0.030
Total number of injections,  mean±SD 12.4±2.7 15.3±4.2 0.013
Intervals between injections,  mean±SD 12.5±4.2 9.6±4.2 0.042
PCV,  polypoidal choroidal vasculopathy; BCVA,  best-corrected visual acuity; LogMAR,  logarithm of the minimum angle of resolution;  
CRT,  central retinal thickness; SD,  standard deviation.
Fig. 1　 A,  Change in 
mean best-corrected 
visual acuity (BCVA) for 
the two groups of 
patients with PCV; B,  
Change in mean central 
retinal thickness for both 
groups.  Circles (black 
line): The PR＋ group 
(n=19).  Squares (gray 
line): The PR－ group 
(n=18).  ＊p=0.001.
nificant (p = 0.03,  Table 2).
Total number of injections and the interval between 
injections. The mean total number of injections in 
the 2-year treatment period was 13.8 ± 3.7,  and the 
mean interval between injections at year 2 was 11.8 ± 4.4 
weeks.  The PR+ group showed significantly fewer 
injections in this period and a significantly longer inter-
val between injections compared to the PR− group.  The 
mean total numbers of injections in the 2-year period in 
the PR+ group and the PR− group were 12.4 ± 2.7 and 
15.3 ± 4.2,  respectively (p = 0.013,  Table 2).  The mean 
intervals between injections at year 2 in the PR+ and 
PR− groups were 12.5 ± 4.2 weeks and 9.6 ± 4.2 weeks,  
respectively (p = 0.042,  Table 2,  Fig. 2).  The interval 
between injections was extended to the maximum 16 
weeks for nine eyes (47.3%) in the PR+ group and for 
three eyes (16.7%) in the PR− group (Fig. 2).
Polyp regression course at 1 year and adverse 
events. In the PR+ group (n = 19) at 1 year,  polypoi-
dal lesions continued to be regressed in 15 eyes (83.3%) 
but recurred in 3 eyes (16.7%); ICGA images were 
unavailable for one of the patients at 1 year due to an 
allergy to ICGA.  In the PR− group (n = 18) at 1 year,  
polypoidal lesions had regressed in 4 eyes (22.2%) and 
had remained in 14 eyes (77.8%).  No serious ocular 
adverse events such as massive subretinal hemorrhage,  
vitreous hemorrhage,  or retinal pigment epithelial tears 
occurred during the follow-up period.  There were no 
systemic complications.  Representative cases are shown 
in Fig. 3 , 4.
Discussion
In this study,  although polyp regression after a load-
ing dose did not affect changes in visual acuity,  the 
patients who exhibited polyp regression had a signifi-
cantly lower PCV recurrence rate,  a significantly smaller 
total number of treatments,  and a significantly longer 
interval between treatments.  These results indicate that 
polyp regression after a loading dose of IVA therapy 
may serve as a reference for estimating the frequency of 
long-term PCV recurrence and the number of anti-
VEGF drug injections.
These findings also indicate that patients who did not 
show polyp regression after the loading dose should 
undergo a TER with a stricter protocol than that used in 
the present study,  in order to prevent the recurrence of 
PCV.  The authors of previous studies described long-
term visual acuity decreases in a PRN of anti-VEGF 
drugs following the recurrence of exudative changes 
[22 , 23].  In the present study,  although the PR− group 
had a significantly higher recurrence rate than the PR+ 
group,  the 2 groups did not differ in visual acuity 
(Table 2).  The lack of difference in visual acuity may 
have been due to the short observation period of only 2 
years.  Therefore,  over the long term,  patients who did 
not exhibit polyp regression may show lower visual acu-
ity than patients who did show polyp regression.  It may 
thus be advisable to make adjustments to the TER pro-
tocol for patients who do not show polyp regression.  
Going forward,  it will be necessary to further clarify the 
factors that affect treatment progress and to establish 
more individualized protocols for TERs.
Here we observed that although the TER of afliber-
cept alone yielded favorable visual acuity,  the mean 
total number of injections in 2 years in the PR− group 
was 15.3±4.2.  Such a high frequency of injections places 
a great burden on the patient.  To resolve this issue,  it 
may be useful to change from aflibercept monotherapy 
to combination therapy with PDT.  Combination ther-
apy with aflibercept and PDT was recently reported to 
require fewer treatments than aflibercept monotherapy 
[24 , 25].  In addition,  PDT is reported to yield a greater 
polyp regression effect than anti-VEGF drugs [5].
However,  the greatest problem with PDT is its risk 
of inducing subretinal hemorrhages,  retinal pigment 
epithelial tears,  and choriocapillaris atrophy [9-11].  
Therefore,  conducting routine PDT in all cases of PCV 
may result in severe complications,  and PDT should 
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Fig. 2　 Distribution of treatment intervals at year 2.
thus be restricted to patients who require it.  In the 
present study,  polyps remained at 1 year in 77.8% of 
the 18 patients who did not show polyp regression after 
the loading dose.  In contrast,  among the group of 19 
patients who showed polyp regression after the loading 
dose,  polyps were still regressed at 1 year in 83.3% of 
the patients.  These results suggest that,  for patients 
who do not demonstrate polyp regression after a load-
ing dose,  combination therapy with PDT may lead to an 
earlier regression of polyps,  a lower frequency of PCV 
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Fig. 3　 Images of the clinical course in the left eye 
of a 73-year-old woman with PCV.  A,C,  At baseline,  
ICGA showed polypoidal lesions (arrow).  Vertical 
images through the fovea taken by OCT showed subret-
inal ﬂuid (arrow) and protrusion of the retinal pigment 
epithelium (RPE) due to a polypoidal lesion (arrow︲
head).  The best-corrected decimal visual acuity was 
0.3; B,D,  After the loading dose (at 3 months after the 
initial treatment),  ICGA showed complete regression of 
the polypoidal lesions.  OCT showed resolution of the 
subretinal ﬂuid and RPE protrusion.  The visual acuity 
was 0.4; E,  At 1 year after the initial treatment,  OCT 
showed no exudative changes.  The visual acuity was 
0.4; F,  Two years after the initial treatment,  OCT 
showed no exudative changes. There was no recur-
rence during the 2 years of follow-up.  The injection 
interval at the ﬁnal visit was 16 weeks,  and the total 
number of injections during the 2 year treatment period 
was 11.  The visual acuity was 0.4.
Fig. 4　 Images of the clinical course in the left eye 
of a 78-year-old woman with PCV.  A,C,  At baseline,  
ICGA showed a polypoidal lesion (arrow).  Horizontal 
images through the fovea taken by OCT showed subret-
inal ﬂuid (arrow) and protrusion of the RPE due to a 
polypoidal lesion (arrowhead).  The best-corrected 
decimal visual acuity was 0.8; B,D,  After the loading 
dose (at 3 months after the initial treatment),  ICGA 
showed no regression of the polypoidal lesions.  
Although OCT showed resolution of the subretinal ﬂuid,  
the RPE protrusion remained.  The visual acuity was 
0.9; E,  At 1 year after the initial treatment,  OCT 
showed recurrence of subretinal ﬂuid (arrow).  The 
visual acuity was 0.9; F,  At 2 years after the initial 
treatment,  although OCT showed no subretinal ﬂuid,  
the RPE protrusion remained.  The injection interval at 
the ﬁnal visit was 4 weeks,  and the total number of 
injections during the 2-year treatment period was 22.  
The visual acuity was 0.9.
recurrence,  and a smaller number of anti-VEGF drug 
injections.
This study has several limitations including its retro-
spective study design and small sample size.  Other 
treatment options for PCV such as PDT or a combina-
tion of PDT and anti-VEGF therapy were not consid-
ered.  Further controlled prospective studies with larger 
sample sizes and longer follow-up periods are needed.  
In conclusion,  we report that polyp regression after a 
loading dose of IVA therapy using a treat-and-extend 
regimen for polypoidal choroidal vasculopathy does not 
affect changes in visual acuity but is associated with 
PCV recurrence,  the total number of anti-VEGF drug 
injections,  and the treatment interval.
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